No Data
The 9.9% Return This Week Takes Mirum Pharmaceuticals' (NASDAQ:MIRM) Shareholders Five-year Gains to 183%
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far more than 100% on a really good stock. For example, the Mirum Pharmaceuticals,
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $69
JMP Securities analyst Jonathan Wolleben maintains $Mirum Pharmaceuticals(MIRM.US)$ with a buy rating, and maintains the target price at $69.According to TipRanks data, the analyst has a success
Mirum Pharmaceuticals (MIRM) Gets a Buy From JMP Securities
Mirum Pharmaceuticals (NASDAQ:MIRM) Delivers Shareholders Solid 23% CAGR Over 5 Years, Surging 11% in the Last Week Alone
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that on July 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase
Express News | Janus Henderson Group Discloses 10.6% Passive Stake In Mirum Pharmaceuticals As Of June 28